Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSCotadutide is a synthetic peptide and dual agonist of the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) that is biased toward GLP-1R.1,2 It increases cAMP accumulation in CHO cells overexpressing recombinant human GLP-1R or GCGR (EC50s = 6.9 and 10.2 pM, respectively).1 It also enhances glucose-stimulated insulin secretion in INS-1 832/3 rat pancreatic β-cells. Cotadutide (10 nmol/kg) reduces food intake and fat mass, as well as improves glucose tolerance in diet-induced obese (DIO) mice. It also reduces food intake and body weight in wild-type but not Glp1r knockout mice, indicating these effects are Glp-1r-dependent, but reduces the hepatic lipid percentage in both wild-type and Glp1r knockout mice, indicating this as a Gcgr-dependent effect.2 Cotadutide (10 nmol/kg) reduces total hepatic triglycerides, diglycerides, cholesterol, and free fatty acids, as well as reduces hepatic inflammation and fibrosis, in an ob/ob mouse model of non-alcoholic steatohepatitis (NASH) induced by a high-trans fat, high-fructose, and high-cholesterol diet.
WARNING This product is not for human or veterinary use.
1. Robust anti-
2. Resolution of NASH and hepatic fibrosis by the GLP-